<DOC>
	<DOCNO>NCT02534844</DOCNO>
	<brief_summary>This study evaluate efficacy safety 2-hydroxypropyl-β-cyclodextrin ( VTS-270 ) patient neurologic manifestation Niemann-Pick Type C1 ( NPC1 ) Disease . Approximately two-thirds patient receive study drug , 2-hydroxypropyl-β-cyclodextrin ( HP-β-CD ) , remain study participant receive sham control .</brief_summary>
	<brief_title>Study VTS-270 ( 2-hydroxypropyl-β-cyclodextrin ) Treat Niemann-Pick Type C1 ( NPC1 ) Disease</brief_title>
	<detailed_description>Non-clinical study Phase 1 clinical trial suggest intrathecal administration 2-hydroxypropyl- β-cyclodextrin ( VTS-270 ) patient neurologic manifestation Niemann-Pick Type C1 ( NPC1 ) disease potential slow rate progression neurologic disease . Niemann-Pick Type C1 ( NPC1 ) disease rare , neurodegenerative , inherited , autosomal recessive lysosomal lipid storage disorder primarily child teenager . The disease characterize inability properly metabolize cholesterol lipid within cell due mutation NPC1 gene cause unesterified cholesterol accumulate brain , liver spleen . This study multicenter , multinational , prospective , randomize , double-blind , sham-controlled , 3-part , efficacy safety trial VTS-270 , administer lumbar intrathecal route ( IT ) every 2 week , plan enrollment approximately 51 subject NPC1 disease . The study conduct three part : Parts A , B , C. Part A evaluate 3 different dose level VTS-270 9 subject 3 sham control subject determine dose level Parts B C. Part B evaluate safety efficacy dose select Part A compare sham control 51 subject , include 12 subject Part A . Part C open-label extension phase study subject either complete Part B subject Part B meet rescue therapy criterion . Subjects Part C receive treatment VTS-270 product license program terminate .</detailed_description>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<criteria>Key Parts A B : 1 . Onset neurological symptom prior 15 year age . 2 . Confirmed diagnosis NPC1 determine either : Two NPC1 mutation ; Positive filipin stain least one NPC1 mutation ; c. Vertical supranuclear gaze palsy ( VSNGP ) combination either : one NPC1 mutation , OR positive filipin stain oxysterol level consistent NPC disease NiemannPick Type C2 ( NPC2 ) Disease mutation . 3 . Subject parent/guardian must provide write informed consent assent ( minor ) . 4 . Ability undergo lumbar puncture ( LP ) IT drug administration conscious sedation general anesthesia . 5 . An NPC Clinical Severity Scale Score 1 4 , inclusive , two follow NPC Severity Scale component : ambulation , fine motor skill , swallow score 0 4 cognition component . 6 . Total NPC Clinical Severity Scale Score 10 great . 7 . If take miglustat , must stable dose past 3 month willing remain stable dose . 8 . Subjects adequately control seizure may qualify enrollment . Subjects history seizure stable pattern seizure activity stable dose regimen anti epileptic medication 3 month prior screen without change dose regimen include Study Day 0 . 9 . Agree discontinue nonprescription supplement Coenzyme Q10 , curcumin , cinnamon , fish oil supplement , high dose vitamin D ( &gt; 500 milliInternational unit ( mIU ) /day ) , acetylleucine , gingko biloba least 1 month prior first dose ( Study Day 0 ) . 10 . Agree discontinue investigational treatment NPC include vorinostat arimoclomol least 3 month prior first dose ( Study Day 0 ) . 11 . Females childbearing potential ( surgically sterile ) must use medically acceptable method contraception must agree continue use method duration study 30 day participation study . Part C : 1 . Subject complete Part B , meet criterion Rescue Option . Key 1 . Exclusion criterion assess NPC Clinical Severity Scale : Unable walk , wheelchair dependent ( ambulation NPC score=5 ) Needs nasogastric tube overcome swallow difficulty ( swallow NPC score=5 ) Note : Nasogastric gastric tube use supplemental feeding medication administration permit exclude subject trial . Severe dysmetria ( fine motor NPC score=5 ) Minimal cognitive function ( cognition NPC score=5 ) . 2 . Body weight &lt; 15 kg . 3 . Prior treatment intravenous 2hydroxypropylβcyclodextrin ( HPβCD ) NPC1 disease , unless subject undergone minimum 3month washout period prior Study Day 0 . Note : Any prior IT administration HPβCD exclude subject enrollment . 4 . Subjects antipsychotics treatment psychosis . Note : Use antipsychotic medication treatment disorder ( e.g. , Attention Deficit Hyperactivity Disorder ) exclude subject trial . 5 . History hypersensitivity reaction product contain 2hydroxypropylβcyclodextrin ( HPβCD ) . 6 . Spinal deformity could impact ability perform lumbar puncture . 7 . Skin infection lumbar region within 2 month study entry . 8 . Neutropenia , define absolute neutrophil count ( ANC ) less 1.5 X 10^9/L . 9 . Thrombocytopenia ( platelet count le 75 X 10^9/L ) . 10 . Activated partial thromboplastin time ( aPTT ) prothrombin time ( PT ) prolong &gt; 1.5 time upper limit normal ( ULN ) know history bleed disorder . 11 . Status epilepticus occur within 3 month screen and/or seizure frequency quantify . 12 . Evidence obstructive hydrocephalus normal pressure hydrocephalus . 13 . Recent use anticoagulant [ past 2 week prior first dose ( Study Day 0 ) ; : lumbar puncture safety ] . 14 . Subjects unable comply study procedures clinical disease laboratory abnormality opinion investigator would potentially increase risk participation .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Niemann-Pick Type C1 ( NPC1 ) Disease</keyword>
	<keyword>neurologic disease</keyword>
	<keyword>gross motor dysfunction</keyword>
	<keyword>fine motor dysfunction</keyword>
	<keyword>dysphagia</keyword>
	<keyword>swallow problem</keyword>
	<keyword>cognitive dysfunction</keyword>
	<keyword>gait abnormality</keyword>
	<keyword>pediatrics</keyword>
</DOC>